This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hrycek, A Articles by Jedynak, P Search for Related Content PubMed PubMed Citation Articles by Hrycek, A Articles by Jedynak, P Social Bookmarking                         What's this?

Selected serum cytokines in systemic lupus erythematosus treated with quinagolide

Department of Internal Diseases and Clinical Pharmacology, University School of Medicine, Katowice, Poland; TysiaÎclecia 86a=34, 40-871 Katowice, Poland.

P Cielik

Department of Internal Diseases and Clinical Pharmacology, University School of Medicine, Katowice, Poland

J Tustanowski

Second Department of Microbiology, University School of Medicine, Katowice, Poland

S Nowak

Department of Isotopic Diagnostics, University School of Medicine, Katowice, Poland

P Jedynak

Department of Internal Diseases and Clinical Pharmacology, University School of Medicine, Katowice, Poland

The objective of this study was to determine the effect of quinagolide (Norprolac) on serum level of cytokines in systemic lupus erythematosus (SLE) patients. In 20 SLE patients treated with a low dose of quinagolide, and in 17 healthy persons who constituted the control group, concentration of serum prolactin (PRL), interleukins (ILs), soluble tumor necrosis factor receptors (sTNF Rs) preceded by calculation of disease activity index (SLEDAI) were tested at entry and then after 3 months in 16 patients and after 6 months in 11 patients who completed the study. Serum PRL level was higher (though insignificantly) in the SLE group than in the controls and decreased significantly after 6 months of therapy. A raised SLEDAI score at entry was significantly reduced during therapy but a weak correlation with PRL level was revealed. A significant increase in IL-6 level in SLE group as compared to controls was observed (respectively 14.57±13.25 and 5.04± 3.35 pg =ml) as well as a significantly decreased level after 6 months of treatment (4.30±2.51 pg =ml). There was a significant difference between sTNF RI concentration before and after 3 months of quinagolide treatment (respectively 1140.83 312.08 and 1454.58±465.54 pg =ml). After 6 months of treatment a statistically significant correlation between concentration of PRL and level of IL-6 and a negative correlation between PRL and sTNF RI was revealed. Quinagolide treatment may have a role in the management of SLE patients. Lupus (2001) 10, 424–430.

Key Words: systemic lupus erythematosus (SLE) • treatment • quinagolide • prolactin (PRL) • cytokines

Lupus, Vol. 10, No. 6, 424-430 (2001)
DOI: 10.1191/096120301678646173


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A Hrycek, D Kokocinska, J Kosmider, and B Konieczny Letter to the Editor Lupus, February 1, 2003; 12(2): 149 - 152. [PDF]